SLC17A5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5622589	0.80	1/20
SCHEMBL14456737	0.80	1/20
SCHEMBL12647474	0.78	1/20
SCHEMBL14456728	0.68	1/20
SCHEMBL5571166	0.66	1/20
SCHEMBL5276812	0.64	1/20
SCHEMBL5622471	0.64	1/20
SCHEMBL5622852	0.64	1/20
SCHEMBL119188	0.61	1/20
SCHEMBL5622593	0.60	1/20
SCHEMBL5051765	0.58	1/20
SCHEMBL178559	0.58	1/20
SCHEMBL178660	0.58	1/20
SCHEMBL12122944	0.58	1/20
SCHEMBL12480413	0.58	1/20
SCHEMBL1486194	0.58	1/20
SCHEMBL14432835	0.56	1/20
SCHEMBL888345	0.56	1/20
SCHEMBL2419146	0.56	1/20
SCHEMBL1738379	0.56	1/20

Clinical trials — most relevant to SLC17A5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study	PHASE1	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers	PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
The Natural History of Sialidosis Type I	nan	RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Sialic Acid in Hepatocellular Carcinoma	nan	NOT_YET_RECRUITING
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy	nan	RECRUITING
Chest Wall Deformities in Children - Epidemiological Data	nan	COMPLETED
The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)	nan	COMPLETED
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study	nan	RECRUITING
Renal Transporters After Renal Transplantation	nan	UNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome	nan	UNKNOWN
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	nan	UNKNOWN
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study	nan	RECRUITING
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3	nan	COMPLETED
Characterization of Breg Cells	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC17A5 binder may also engage these)

Protein	Name	Similarity
Q5Q0U0	—	0.999	Q5Q0U0 →
Q9MZD1	—	0.998	Q9MZD1 →
Q8BN82	—	0.997	Q8BN82 →
B0WC46	—	0.961	B0WC46 →
B4HNS1	—	0.959	B4HNS1 →
B4QBN3	—	0.955	B4QBN3 →
Q8MKK4	—	0.954	Q8MKK4 →
A5LGM7	—	0.950	A5LGM7 →
P79365	—	0.950	P79365 →
Q9WVR6	—	0.948	Q9WVR6 →
Q9N1Q4	—	0.948	Q9N1Q4 →
Q5M7K3	—	0.947	Q5M7K3 →
P46896	—	0.947	P46896 →
O62787	—	0.947	O62787 →
P47843	—	0.946	P47843 →
P13355	—	0.945	P13355 →
Q9QXW9	—	0.945	Q9QXW9 →
Q8AVC3	—	0.944	Q8AVC3 →
P20303	—	0.944	P20303 →
A2SWM2	—	0.944	A2SWM2 →
P27674	—	0.944	P27674 →
P17809	—	0.943	P17809 →
SLC2A1	Solute carrier family 2, facilitated glucose transporter member 1	0.943	landscape →
Q5RAE3	—	0.943	Q5RAE3 →
Q9UHI5	—	0.943	Q9UHI5 →
Q7ZU13	—	0.943	Q7ZU13 →
P11167	—	0.943	P11167 →
P57057	—	0.942	P57057 →
Q8R070	—	0.942	Q8R070 →
Q7SY29	—	0.942	Q7SY29 →